GMO forecasts
The new GMO asset class return forecasts are out.
The new ones, are just like the old ones.
I suppose they are sticking faithfully to their process, and I don’t really know how they set/structure/implement based on these SAA inputs, but obviously you would have absolutely done your dough had you followed the implied outcomes (in other words, they’ve been very negative for about the last 10 years, and the portfolio outcomes would have been so far behind the benchmark as to be unworkable).
Whenever you are feeling bearish, which happens all the time in this job, such data is “latch-able, grab-able, anchors you” quite quickly. We want to be mindful of what other investors are thinking, and indeed a part of our long run capital market assumptions come from “what do we think, and why”, and “what do others think, and why”.
Perhaps an implied takeaway is one we already follow, namely, diversify. We’ve got some value tilts on, we’ve got the corollary, which is an underweight to growth, we’ve got a bit less US equities than the benchmark, we’ve got a bit more Europe, Japan, even the UK, than the benchmark, we’ve started allocating a little bit to credit, we even bought a very small amount of gold exposure (producers) in our direct equity sleeves.
All at the margin.
Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Please note that past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.